<DOC>
	<DOCNO>NCT00545051</DOCNO>
	<brief_summary>This 2 arm study investigate efficacy safety Bonviva ( 150mg po monthly ) prevention glucocorticoid-induced osteoporosis post-menopausal woman . Patients randomize receive either Bonviva 150mg po placebo monthly , vitamin D calcium supplementation . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Once Monthly Bonviva ( Ibandronate ) Prevention Glucocorticoid-Induced Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>postmenopausal woman , 5085 year age ; inflammatory rheumatoid disease include polymyalgia rheumatica ; receive treatment 515 mg/day prednisolone . previous treatment iv bisphosphonate time ; previous treatment oral bisphosphonate within last 6 month , &gt; 1 month treatment within last year , &gt; 3 month treatment within last 2 year ; treatment parathyroid hormone last 2 year ; inability stand sit upright position least 60 minute ; inability swallow tablet whole ; history major gastrointestinal disease .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>